NCT04704453View on ClinicalTrials.gov

Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

April 28, 2025

Study Completion Date

April 28, 2025

Conditions
Head and Neck Cancer
Interventions
DRUG

Capsaïcin patch (Qutenza®)

Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).

DRUG

Amitriptyline (Laroxyl®)

Treatment by amitriptyline (oral solution 40mg/ml), for 9 months at the recommended dose of 25 mg to 75 mg daily.

Trial Locations (4)

13285

Hôpital Saint-Joseph, Marseille

31059

Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse

Unknown

INSTITUT DE CANCEROLOGIE DE L'OUEST (ICO) Site Angers, Angers

Institut Sainte-Catherine, Avignon

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER